Sorafenib-Based Drug Delivery Systems: Applications and Perspectives

As a Food and Drug Administration (FDA)-approved molecular-targeted chemotherapeutic drug, sorafenib (SF) can inhibit angiogenesis and tumor cell proliferation, leading to improved patient overall survival of hepatocellular carcinoma (HCC). In addition, SF is an oral multikinase inhibitor as a singl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lingyun, Chen, Meihuan, Ran, Xueguang, Tang, Hao, Cao, Derong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303456/
https://www.ncbi.nlm.nih.gov/pubmed/37376284
http://dx.doi.org/10.3390/polym15122638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10303456/
https://www.ncbi.nlm.nih.gov/pubmed/37376284
http://dx.doi.org/10.3390/polym15122638

Ejemplares similares